Monte Rosa Therapeutics, Inc. GLUE
Set alert
10.55 USD -0.08 -0.74%
As of Nov 3, 1:04 PM ET
10.52 Day range 10.90
9.68 52-week range 25.77
- YTD
- -32.71%
- 1 year
- -12.58%
- Open
- 10.90
- Prev close
- 10.63
- Mkt cap
- 900.91M
- Vol
- 446.81K
- Avg vol
- 1.30M
- EPS
- -1.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.52
- High
- 10.90
- Forward P/E
- -6.37
- Beta
- 1.50
- Short ratio
- 17.13
- Inst. own
- 116.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 15.55
- 200-d avg
- 18.27
- 1y target
- 28.50
Analyst view
Price target (mean) 28.50 +170.1% upside
Now 10.55
- Target (low)
- 25.00
- Target (mean)
- 28.50
- Target (high)
- 37.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.22694 | -0.56 – 0.10143 | -0.33 | +31.2% | 31.14M | +143.9% | 7 |
| Next quarter | -0.36541 | -0.59 – 0.38215 | -0.55 | +33.6% | 21.63M | +677.9% | 7 |
| Current year | -1.44 | -2.02 – -0.41463 | -0.46 | -214.1% | 65.89M | -46.7% | 7 |
| Next year | -1.87 | -2.91 – 0.24018 | -1.44 | -29.7% | 57.07M | -13.4% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 25, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 3, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jun 30, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 18, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 18, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jan 14, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jan 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jan 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 16, 2025 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Nov 7, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 21, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 21, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Mar 12, 2025 | LifeSci Capital | Initiated | — | Outperform |
| Dec 19, 2024 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Sep 12, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 12, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Jun 28, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| May 22, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 15, 2024 | Wedbush | Initiated | — | Outperform |
| Oct 19, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 11, 2023 | Credit Suisse | Reiterated | Neutral | Neutral |
| May 12, 2023 | Credit Suisse | Reiterated | Neutral | Neutral |
| Mar 17, 2023 | Credit Suisse | Maintained | — | Neutral |
| Jan 3, 2023 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Oct 13, 2022 | UBS | Initiated | — | Buy |